Oral Nintedanib for Refractory Generalized Keloids: A Prospective Exploratory Pilot Study
Open Access
- 26 August 2026
- journal article
- research article
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (9) , e71107
Abstract
Background: Generalized keloids are severe, treatment‐refractory, disfiguring dermatoses that substantially impair physical and psychosocial well‐being and have limited effective systemic treatment options. Objective: To assess the short‐term safety, tolerability, and exploratory clinical outcomes of oral nintedanib in patients with refractory generalized keloids. Methods: In this single‐center, open‐label, assessor‐blinded exploratory pilot study, 10 adults with refractory generalized keloids received oral nintedanib 150 mg once daily or 150 mg twice daily for 8 weeks. The primary exploratory endpoint was change in Vancouver scar scale (VSS) score from baseline to Week 8. Secondary endpoints included pruritus and pain visual analogue scale (VAS) scores, patient and observer scar assessment scale (POSAS), dermatology life quality index (DLQI), imaging and histological assessments, and safety outcomes. Results: All participants completed treatment and follow‐up. Mean VSS scores decreased from 11.2 ± 1.3 to 8.2 ± 1.1 in the low‐dose group and from 10.4 ± 1.8 to 8.2 ± 1.9 in the high‐dose group. Pruritus severity and visible scar vascularity showed numerical improvements over 8 weeks, whereas POSAS and DLQI changed little. Histological assessment suggested reduced cellularity and more organized collagen architecture after treatment. No serious adverse events or treatment discontinuations occurred; the most common treatment‐related adverse events were mild diarrhea and transient transaminase elevation. Conclusion: In this small, uncontrolled exploratory pilot study, oral nintedanib was associated with early favorable changes in selected clinician‐rated and symptom‐based outcomes, whereas POSAS and DLQI showed limited short‐term change. These findings are preliminary and hypothesis‐generating and warrant confirmation in larger controlled studies with longer treatment and follow‐up.Keywords
Funding Information
- National Natural Science Foundation of China (82303064)
This publication has 16 references indexed in Scilit:
- Bevacizumab as Adjuvant Therapy in the Treatment of Keloid: A Randomized Clinical TrialDermatologic Therapy, 2024
- Decoding the molecular landscape of keloids: new insights from single-cell transcriptomicsBurns & Trauma, 2023
- Risk single-nucleotide polymorphism-mediated enhancer–promoter interaction drives keloids through long noncoding RNA down expressed in keloidsBritish Journal of Dermatology, 2022
- Single-Cell RNA-Sequencing Reveals Lineage-Specific Regulatory Changes of Fibroblasts and Vascular Endothelial Cells in KeloidsJournal of Investigative Dermatology, 2022
- Nintedanib in Progressive Fibrosing Interstitial Lung DiseasesNew England Journal of Medicine, 2019
- Nintedanib for Systemic Sclerosis–Associated Interstitial Lung DiseaseNew England Journal of Medicine, 2019
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Individual patient data analysis to assess modifications to the RECIST criteriaEuropean Journal of Cancer, 2009
- Keloid disease: clinical relevance of single versus multiple site scarsBritish Journal of Plastic Surgery, 2005